NEW YORK (GenomeWeb News) – Goldman Sachs today downgraded Agilent Technologies and Genomic Health, but upgraded Waters.

The changes to the three firms' ratings are part of a "recalibrating" of the investment bank's Life Science Tools portfolio in light of tighter credit in China and an "underappreciated risk" of renewed austerity as the US Fiscal Year 2014 budget and debt ceiling "come back into focus," analyst Isaac Ro said in a research report.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.